SEC Form 4 · accession 0002124755-26-000007
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Scott Chin
Officer — Chief Medical Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 4:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | Sep 4, 2026 | S | 1,654 | $22.29 | D | 204,538 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3Includes 142,845 Unvested RSU's
- F4Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.